Compare · COR vs HKPD
COR vs HKPD
Side-by-side comparison of Cencora Inc. (COR) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR carries a market cap of $7.54B.
- Over the past year, COR is up 7.1% and HKPD is down 28.6% - COR leads by 35.7 points.
- HKPD has hit the wire 1 time in the past 4 weeks while COR has been quiet.
- COR has more recent analyst coverage (24 ratings vs 0 for HKPD).
- Company
- Cencora Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- $308.18-1.04%
- $0.65-12.02%
- Market cap
- $7.54B
- -
- 1M return
- -5.21%
- +0.03%
- 1Y return
- +7.11%
- -28.57%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 24
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- SEC Form 4 filed by Krikorian Lazarus
- Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
- Amendment: SEC Form SCHEDULE 13G/A filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business
- Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Announces Financial Leadership Transition
- Executive Vice President Battaglia Silvana converted options into 8,415 shares and covered exercise/tax liability with 3,673 shares, increasing direct ownership by 25% to 23,566 units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S converted options into 12,623 shares and covered exercise/tax liability with 5,842 shares, increasing direct ownership by 28% to 30,706 units (SEC Form 4)
- Chief Financial Officer Cleary James F covered exercise/tax liability with 5,409 shares and converted options into 12,623 shares, increasing direct ownership by 5% to 160,357 units (SEC Form 4)
Latest HKPD
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited